Trial · NCT03126539
Effect of Topical Sulforaphane on Skin Fragility Seen in Skin Aging and With Ultraviolet Exposure
NCT03126539, Phase 2, Terminated, Johns Hopkins University; results first posted 2020-02-25
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Topical Sulforaphane on Skin Fragility Seen in Skin Aging and With Ultraviolet Exposure. Trials, record NCT03126539. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03126539
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Topical Sulforaphane on Skin Fragility Seen in Skin Aging and With Ultraviolet Exposure
- NCT number
- NCT03126539
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 9 participants, actual
- Lead sponsor
- Johns Hopkins University
- Conditions
- Aging
- Interventions
- Sulforaphane, Narrow-band Ultraviolet B exposure, 4 mm skin punch biopsy
- First posted
- 2017-04-24
- Last updated
- 2023-06-29
- Results first posted
- 2020-02-25
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical Change Score for Mottled Hyperpigmentation | Clinical Change Score for Mottled Hyperpigmentation , up to 1 week | Clinical assessment of mottled hyperpigmentation pre and post Sulforaphane (SF) treatment will be done for both photoprotected and photodamaged skin treated with sulforaphane. Mottled Hyperpigmentation Score system will be applied, with scale of 0 to 4, 4= clear improvement after 1 week of SF or placebo application. |
| Secondary | Gene Expression Changes as Assessed by Quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR) | Up to 6 months | We will measure the fold-change in gene expression in human skin after acute UV light exposure, separately and in combination with application of topical sulforaphane using RT-PCR. |
| Secondary | Gene Expression Changes as Assessed by Immunohistochemistry (IHC) | Up to 6 months | We will measure the fold-change in gene expression in human skin after acute UV light exposure, separately and in combination with application of topical sulforaphane using IHC. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Clinical Change Score for Mottled Hyperpigmentation | Clinical Change Score for Mottled Hyperpigmentation , up to 1 week | We did not enroll any participant in group B. The results we got were not the comparison between no UV exposure group and UV exposure. Instead, the results were the clinical change score between the SF treated skin spots and no SF treated (placebo) skin spots of each participant. | score on a scale | MEAN |
| SECONDARY | Gene Expression Changes as Assessed by Quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR) | Up to 6 months | Data for this outcome measure was not collected. | ||
| SECONDARY | Gene Expression Changes as Assessed by Immunohistochemistry (IHC) | Up to 6 months | Data for this outcome measure was not collected. |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Clinical Change Score for Mottled Hyperpigmentation | Group A: No UV Exposure - Sulforaphane | 2.8 | Standard Error 0.4 | score on a scale | |
| Clinical Change Score for Mottled Hyperpigmentation | Group A: No UV Exposure - Placebo | .94 | Standard Error .2 | score on a scale | |
| Clinical Change Score for Mottled Hyperpigmentation | Group A: No UV Exposure - No Treatment Control | 0 | Standard Error 0 | score on a scale |
Source ClinicalTrials.gov
Participant flow15
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Group A: No UV Exposure - Sulforaphane | 9 | 9 |
| Overall Study | STARTED | Group A: No UV Exposure - Placebo | 9 | 9 |
| Overall Study | STARTED | Group A: No UV Exposure - No Treatment Control | 9 | 27 |
| Overall Study | STARTED | Group B With UV Exposure - Sulforaphane | 0 | 0 |
| Overall Study | STARTED | Group B With UV Exposure - Placebo | 0 | 0 |
| Overall Study | COMPLETED | Group A: No UV Exposure - Sulforaphane | 8 | 8 |
| Overall Study | COMPLETED | Group A: No UV Exposure - Placebo | 8 | 8 |
| Overall Study | COMPLETED | Group A: No UV Exposure - No Treatment Control | 8 | 24 |
| Overall Study | COMPLETED | Group B With UV Exposure - Sulforaphane | 0 | 0 |
| Overall Study | COMPLETED | Group B With UV Exposure - Placebo | 0 | 0 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Group A: No UV Exposure | 0 | 9 |
| Total, all-cause mortality | Group B With UV Exposure | 0 | 0 |
| Total, other adverse events | Group A: No UV Exposure | 0 | 9 |
| Total, other adverse events | Group B With UV Exposure | 0 | 0 |
| Total, serious adverse events | Group A: No UV Exposure | 0 | 9 |
| Total, serious adverse events | Group B With UV Exposure | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03126539
GET https://conductscience.org/api/trials/v1/NCT03126539/registered